Author:
Maier S.,Strasser S.,Saiko P.,Leisser C.,Sasgary S.,Grusch M.,Madlener S.,Bader Y.,Hartmann J.,Schott H.,Mader R. M.,Szekeres T.,Fritzer-Szekeres M.,Krupitza G.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry, medical,Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference35 articles.
1. Momparler RL. A model for the chemotherapy of acute leukemia with 1-beta-D- arabinofuranosylcytosine. Cancer Res 1974; 34(8): 1775–1787.
2. Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982; 42(4): 1587–94.
3. Saiko P, Horvath Z, Illmer C, Madlener S, et al. Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk Res 2005; 29(7): 785–791.
4. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485–493.
5. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86(9): 1367–1372.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献